The demand for urban transport: An application of discrete choice model for Cadiz

The study of the demand for transport has among others applications, the valuation of travel time saving that is a very important question in cost-benefit analysis, and to adopt transport policy tools. Since McFadden developed a discrete choice model for travel demand, it has usually been the application of this model to study the individual behaviour when he has to choice among transport modes. Citizens of big cities have to face traffic congestion; pollution, wasted time in travels and fuel, noise, stress and accidents are the costs imposed by congestion to society, elements that reduce the quality of life in cities. Public transport is a real alternative to private transport that is socially less expensive, for this reason this paper tries to forecast travel demand for public transport in Cadiz when travelling have to choice between public or private transport, using a discrete choice model. The results of this analysis (travel demand, value of time, elasticities) can be used to design transport policies that could reduce congestion.

The demand for urban transport: An application of discrete choice model for Cadiz

The study of the demand for transport has among others applications, the valuation of travel time saving that is a very important question in cost-benefit analysis, and to adopt transport policy tools. Since McFadden developed a discrete choice model for travel demand, it has usually been the application of this model to study the individual behaviour when he has to choice among transport modes. Citizens of big cities have to face traffic congestion; pollution, wasted time in travels and fuel, noise, stress and accidents are the costs imposed by congestion to society, elements that reduce the quality of life in cities. Public transport is a real alternative to private transport that is socially less expensive, for this reason this paper tries to forecast travel demand for public transport in Cadiz when travelling have to choice between public or private transport, using a discrete choice model. The results of this analysis (travel demand, value of time, elasticities) can be used to design transport policies that could reduce congestion

TECHNOLOGICAL CAPABILITIES AND PATTERNS OF INCOME CONVERGENCE IN EUROPE: A CLUSTER ANALYSIS

This paper analyses the patterns of convergence across the European Union countries in terms of both economic growth and technological conditions during the period 1995-2013. We apply the methodology of Phillips-Sul (2007) to study convergence in real income per capita and countries’ technological capabilities. We consider separately eight technological indicators as proxies for a country's innovative ability and absorptive capacity. The results support the club convergence hypothesis for income and some technology-related indicators, and offer an approximation to the role that technological capabilities could play in the income convergence process

Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study

This multicenter, double-blind, randomized study compared the efficacy, pharmacokinetics (PKs)/pharmacodynamics (PDs), safety and immunogenicity profile of RTXM83 vs. reference rituximab (R-rituximab), both with CHOP, as first-line treatment of diffuse large B-cell lymphoma (DLBCL). A total of 272 patients <65 years of age, with good prognosis (136 per arm) were randomized (1:1) to receive six cycles of either RTXM83 or R-rituximab. The primary efficacy endpoint was achieved (overall response rate of 83.6% for RTXM83 and 82.9% for R-rituximab) with a difference 0.7% between arms (95%CI: [-8.77% to 10.17%]) fulfilling the predefined non-inferiority margin (-13%). Similar number of patients reported at least one adverse event (AE) (131 per arm) or one serious AE (47 with RTXM83 and 45 with R-rituximab). Anti-drug antibody development was comparable between the arms. PK/PD secondary endpoint results support similarity between the compounds. RTXM83 exhibits non-inferior efficacy and similar safety/immunogenicity to R-rituximab, being an accessible alternative for the treatment of patients with previously untreated DLBCL